At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies.
The causes and consequences of tumour evolution and heterogeneity
15th October 2015
Oncology
Join our mailing list
To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now